<DOC>
	<DOCNO>NCT02151370</DOCNO>
	<brief_summary>This observational study collect data safety female patient advance ovarian epithelial cancer measurable residual disease surger . The treat physician decide treat patient Avastin ( bevaci zumab ) combination chemotherapy follow Avastin monotherapy accordin g local label . Data collect 72 week .</brief_summary>
	<brief_title>An Observational Study Avastin ( Bevacizumab ) Patients With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Female patient 18 year age Histologically confirm Advanced Epithelial Ovarian Cancer Confirmed ascites prior surgery Residual disease surgery Patients chemotherapy na√Øve receive one prior line treatment disease International Federation Gynecology Obstetrics ( FIGO ) stage IIIb IV disease Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 Patients must meet treatment eligibility requirement accord treat physician Summary Product Characteristics ( SmPC ) criteria Avastin plus chemotherapy . Pregnancy lactation Low grade tumor , since necessarily require systemic treatment . Complete surgical resection Uncontrollable hypertension Unexplained bleed Known hypersensitivity component bevacizumab All contraindication specify respective Summary Product Characteristics ( SmPC ) and/or local labelling Avastin correspond chemotherapy must adhere physician .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>